Variables | Treatment cohorts | ||
---|---|---|---|
Maximum tolerable dose (n = 35) | Metronomic dose (n = 19) | Overall (n = 54) | |
Age (years) | |||
Mean ± SD | 51.3 ± 11.1 | 47.4 ± 10.8 | 49.9 ± 11.1 |
Tumor Size (cm) | |||
Mean ± SD | 3.8 ± 1.9 | 3.0 ± 1.3 | 3.5 ± 1.7 |
Location | |||
Left | 15 (43%) | 10 (53%) | 25 (46%) |
Right | 20 (57%) | 9 (47%) | 29 (54%) |
Histology | |||
IDC | 31 (89%) | 18 (95%) | 49 (91%) |
ILC | 4 (11%) | 1 (5%) | 5 (9%) |
Receptor status | |||
ER | |||
− | 13 (37%) | 5 (26%) | 18 (33%) |
+ | 21 (60%) | 14 (74%) | 35 (65%) |
PR | |||
− | 15 (42%) | 8 (42%) | 23 (43%) |
+ | 19 (54%) | 11 (58%) | 30 (56%) |
HER2 | |||
− | 24 (69%) | 14 (74%) | 38 (70%) |
+ | 10 (29%) | 5 (26%) | 15 (28%) |
Unknown receptor (ER,PR,HER2) | 1 (2%) | 0 | 1 (2%) |
Pathologic response | |||
Complete response | 10 (29%) | 5 (26%) | 15 (28%) |
Partial response | 15 (43%) | 5 (26%) | 20 (37%) |
No response | 10 (29%) | 9 (47%) | 19 (35%) |
Treatment | |||
AC | 30 (86%) | 0 | 30 (56%) |
AC + DTX | 3 (9%) | 0 | 3 (6%) |
Cb + DTX + Tr | 1 (3%) | 0 | 1 (2%) |
Cb + nPTX+Bev | 0 | 14 (74%) | 14 (26%) |
Cb + nPTX+Tr | 0 | 5 (26%) | 5 (9%) |
Pzb + DTX + Tr | 1 (3%) | 0 | 1 (2%) |
Institute | |||
UC Irvine | 29 (83%) | 19 (100%) | 48 (89%) |
Boston Medical Center | 6 (17%) | 0 | 6 (11%) |